Pfizer Inc Cdr Stock Book Value Per Share
| PFE Stock | 11.94 0.26 2.23% |
Pfizer Inc CDR fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.
Pfizer | Book Value Per Share |
Pfizer Inc CDR Company Book Value Per Share Analysis
Pfizer's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Pfizer Book Value Per Share | 16.29 X |
Most of Pfizer's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc CDR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Pfizer Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Pfizer Inc CDR is about 16.288 times. This is 1058.12% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The book value per share for all Canada stocks is 99.16% higher than that of the company.
Pfizer Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in book value per share category among its peers.
Pfizer Fundamentals
| Return On Equity | 0.0454 | ||||
| Return On Asset | 0.0331 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 282.45 B | ||||
| Shares Outstanding | 16.69 B | ||||
| Price To Book | 1.54 X | ||||
| Price To Sales | 3.36 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 18.37 B | ||||
| Net Income | 2.12 B | ||||
| Total Debt | 10.35 B | ||||
| Book Value Per Share | 16.29 X | ||||
| Cash Flow From Operations | 12.04 B | ||||
| Earnings Per Share | 0.36 X | ||||
| Price To Earnings To Growth | 0.18 X | ||||
| Number Of Employees | 88 K | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 199.25 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Annual Yield | 0.07 % | ||||
| Net Asset | 226.5 B | ||||
| Last Dividend Paid | 1.67 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc CDR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc CDR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Pfizer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.Moving against Pfizer Stock
| 0.73 | TD-PFI | Toronto Dominion Bank | PairCorr |
| 0.66 | AMZN | Amazon CDR | PairCorr |
| 0.63 | BNS | Bank of Nova Scotia | PairCorr |
| 0.6 | BMO | Bank of Montreal | PairCorr |
| 0.45 | RY | Royal Bank | PairCorr |
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Pfizer Stock
Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.